About Cardio Flow
An innovative company dedicated to developing a new approach to orbital atherectomy for the treatment of peripheral artery disease
Cardio Flow, Inc., is a privately held commercial-stage medical device company located in St. Paul, MN, which designs and develops minimally invasive peripheral vascular products with the goal of providing physicians with better treatment options for peripheral artery disease (PAD) to improve patient lives.
Cardio Flow’s market-disruptive FreedomFlow® Orbital Atherectomy Platform received FDA clearance in September, 2023, and provides physicians with a highly efficient, effective, and flexible way to treat complex PAD in a wide range of vessel diameters—from 2 mm in the ankle to 8 mm in the hip.
The simplicity and sophistication of the platform also offers time savings and costs efficiencies, making it the ideal choice for today’s hospitals, ambulatory surgical centers, and office-based labs.
An extensive intellectual property portfolio
Cardio Flow, Inc., founded in 2014, has developed an extensive intellectual property portfolio for this new technology, including 40 issued U.S. patents, 2 pending U.S. patents, and 6 published U.S. patents.
A governing Board with extensive experience in the atherectomy market
Cardio Flow’s six-member Board of Directors has extensive experience in developing and bringing new medical technologies to market, including atherectomy devices.
This group includes investment executive Gary Petrucci, who founded the company that has become Cardiovascular Systems, Inc. (CSI), now part of Abbott, and Dr. Michael Kallok, who was CEO of CSI until 2007 and who took the company from start-up status to a market cap of $300 million.
Gary M. Petrucci
Chairman and Founder
Jihad A. Mustapha, M.D.
Director and Chief Medical Officer
Michael J. Kallok, Ph.D.
Steven C. Simon